Silence Therapeutics (NASDAQ:SLN – Get Free Report)‘s stock had its “overweight” rating restated by equities research analysts at Morgan Stanley in a report issued on Monday, Benzinga reports. They currently have a $45.00 target price on the stock. Morgan Stanley’s price objective points to a potential upside of 99.91% from the stock’s current price.
Other analysts also recently issued research reports about the company. BMO Capital Markets started coverage on Silence Therapeutics in a research note on Wednesday, January 31st. They set an “outperform” rating and a $67.00 price target on the stock. HC Wainwright reiterated a “buy” rating and set a $75.00 price target on shares of Silence Therapeutics in a research note on Friday, March 15th. Finally, Chardan Capital boosted their price target on Silence Therapeutics from $26.00 to $42.00 and gave the company a “buy” rating in a research note on Thursday, March 14th.
Check Out Our Latest Report on SLN
Silence Therapeutics Stock Up 0.0 %
Silence Therapeutics (NASDAQ:SLN – Get Free Report) last announced its earnings results on Wednesday, March 13th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.22). Silence Therapeutics had a negative return on equity of 262.17% and a negative net margin of 171.41%. The business had revenue of $2.61 million for the quarter, compared to analysts’ expectations of $11.46 million. On average, research analysts expect that Silence Therapeutics will post -1.38 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Silence Therapeutics
Several institutional investors and hedge funds have recently modified their holdings of SLN. Lynx1 Capital Management LP acquired a new position in shares of Silence Therapeutics in the 3rd quarter valued at about $2,315,000. SG Americas Securities LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at about $110,000. Vivo Capital LLC acquired a new position in shares of Silence Therapeutics in the 4th quarter valued at about $8,862,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in shares of Silence Therapeutics by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 232,942 shares of the company’s stock valued at $4,046,000 after buying an additional 40,063 shares during the period. Institutional investors and hedge funds own 98.73% of the company’s stock.
Silence Therapeutics Company Profile
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.
See Also
- Five stocks we like better than Silence Therapeutics
- What is a Secondary Public Offering? What Investors Need to Know
- Charles Schwab Fortifies its Uptrend on EPS Beat
- The Significance of Brokerage Rankings in Stock Selection
- Lockheed Martin Stock Aims for a Fresh All-Time High
- What is a Death Cross in Stocks?
- Beyond the Halving: The Future of Bitcoin Mining Stocks
Receive News & Ratings for Silence Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Silence Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.